Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guy Griebel

Showing results (31-40 of 68) with videos related to

Pageof 7
Sort By:
Behavioural Pharmacology|August 10, 2013
Phencyclidine decreases tickling-induced 50-kHz ultrasound vocalizations in juvenile rats: a putative model of the negative symptoms of schizophrenia?Denis Boulay, Sophie Ho-Van, Olivier Bergis, et al.
Frontiers in Endocrinology|May 1, 2014
Mice deficient in cryptochrome 1 (cry1 (-/-)) exhibit resistance to obesity induced by a high-fat dietGuy Griebel, Christine Ravinet-Trillou, Sandra Beeské, et al.
Pharmacology, Biochemistry, and Behavior|November 30, 2007
Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-modelsCaroline Louis, Jeanne Stemmelin, Denis Boulay, et al.
Current Drug Targets. CNS and Neurological Disorders|May 29, 2003
The vasopressin V1b receptor as a therapeutic target in stress-related disordersGuy Griebel, Jacques Simiand, Jeanne Stemmelin, et al.
Trends in Pharmacological Sciences|November 11, 2003
Neuropeptide systems as novel therapeutic targets for depression and anxiety disordersAndrew Holmes, Markus Heilig, Nadia M J Rupniak, et al.
Pharmacology, Biochemistry, and Behavior|October 6, 2010
SSR181507, a dopamine D₂ receptor and 5-HT(₁A) receptor ligand: evidence for mixed anxiolytic- and antidepressant-like activitiesDenis Boulay, Ronan Depoortere, Caroline Louis, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 23, 2009
Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophreniaSegev Barak, Michal Arad, Amaya De Levie, et al.
Neuroscience Letters|September 21, 2010
Effects of intra-hippocampal injections of the NK2 receptor antagonist saredutant on the elevated plus maze, and the mouse defense test batteryKarina Genaro Borelli, Erwin B Defensor, D Caroline Blanchard, et al.
Pharmacology, Biochemistry, and Behavior|January 18, 2005
AVP V1b selective antagonist SSR149415 blocks aggressive behaviors in hamstersRobert J Blanchard, Guy Griebel, Catherine Farrokhi, et al.
Pharmacology, Biochemistry, and Behavior|March 10, 2004
Effects of the CRF1 antagonist SSR125543A on aggressive behaviors in hamstersCatherine Farrokhi, D Caroline Blanchard, Guy Griebel, et al.
Pageof 7

Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
Behavioural Pharmacology|August 10, 2013
Phencyclidine decreases tickling-induced 50-kHz ultrasound vocalizations in juvenile rats: a putative model of the negative symptoms of schizophrenia?Denis Boulay, Sophie Ho-Van, Olivier Bergis, et al.
Frontiers in Endocrinology|May 1, 2014
Mice deficient in cryptochrome 1 (cry1 (-/-)) exhibit resistance to obesity induced by a high-fat dietGuy Griebel, Christine Ravinet-Trillou, Sandra Beeské, et al.
Pharmacology, Biochemistry, and Behavior|November 30, 2007
Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-modelsCaroline Louis, Jeanne Stemmelin, Denis Boulay, et al.
Current Drug Targets. CNS and Neurological Disorders|May 29, 2003
The vasopressin V1b receptor as a therapeutic target in stress-related disordersGuy Griebel, Jacques Simiand, Jeanne Stemmelin, et al.
Trends in Pharmacological Sciences|November 11, 2003
Neuropeptide systems as novel therapeutic targets for depression and anxiety disordersAndrew Holmes, Markus Heilig, Nadia M J Rupniak, et al.
Pharmacology, Biochemistry, and Behavior|October 6, 2010
SSR181507, a dopamine D₂ receptor and 5-HT(₁A) receptor ligand: evidence for mixed anxiolytic- and antidepressant-like activitiesDenis Boulay, Ronan Depoortere, Caroline Louis, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 23, 2009
Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophreniaSegev Barak, Michal Arad, Amaya De Levie, et al.
Neuroscience Letters|September 21, 2010
Effects of intra-hippocampal injections of the NK2 receptor antagonist saredutant on the elevated plus maze, and the mouse defense test batteryKarina Genaro Borelli, Erwin B Defensor, D Caroline Blanchard, et al.
Pharmacology, Biochemistry, and Behavior|January 18, 2005
AVP V1b selective antagonist SSR149415 blocks aggressive behaviors in hamstersRobert J Blanchard, Guy Griebel, Catherine Farrokhi, et al.
Pharmacology, Biochemistry, and Behavior|March 10, 2004
Effects of the CRF1 antagonist SSR125543A on aggressive behaviors in hamstersCatherine Farrokhi, D Caroline Blanchard, Guy Griebel, et al.
Pageof 7